SISTEM
Sarcopenic syndrome with multimorbidity: prevention and management of chronic disease with naturally derived bioactive molecules of synergistic action.
SISTEM develops natural bioactive compounds for the prevention and treatment of sarcopenia through eco-sustainable approaches and personalised-medicine models.
The project
The SISTEM project is a Research and Development (R&D) project that focused onthe formulation of new therapeutic strategies for the prevention and treatment of sarcopenic syndrome through the use of naturally derived bioactive compounds obtained through eco-sustainable extraction processes. Sarcopenia, as defined by the European Working Group on Sarcopenia in Older People (EWGSOP), is a multifactorial disorder characterised by the progressive and generalised loss of muscle mass, strenght, and physical function. It represents one of the main causes of physical frailty in the elderly population, but it can also be observed in younger individuals, particulary in individuals affected by endocrine and metabolic disorders
Il progetto integra competenze di biotecnologia, farmacologia, nutrizione clinica e medicina personalizzata al fine di identificare formulazioni innovative in grado di contrastare la perdita di massa e funzione muscolare. The project integrates expertise in biotechnology, pharmacology, clinical nutrition and personalised medicine in order to identify innovative formulations capable of preventing or mitigating the decline in muscle mass and physical function.The activities include in-vitro and ex-vivo studies and clinical trials on pre-sarcopenic subjects, with particular attention to the tolerability, safety and efficacy of the selected molecules.
Results
SISTEM aims at the design and validation of innovative formulations based on natural phytocomplexes and bioactive compounds with potential anti-sarcopenic activity. The main objectives include the identification of clinical and metabolic biomarkers associated with the progression of sarcopenia, the development of eco-sustainable extraction processes, the purification of non-psychotropic cannabinoids and other bioactive compounds, and the definition of personalised therapeutic combinations according to the patient's comorbidities. The project will contribute to the development of innovative personalised-medicine approaches aimed at improving the quality of life of elderly and frail patients, reducing the risk of disability, hospitalisation and functional decline Significant results are also expected in terms of technology transfer between the research bodies and companies involved, with potential industrial applications in the nutraceutical, biomedical and pharmaceutical sectors.
